{"symbol":"MRK","fiscalQuarter":"Q2-2026","reportDate":"2026-08-04","reportTime":"BMO","status":"upcoming","company":{"name":"Merck & Co., Inc.","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/MRK/earnings/Q2-2026","estimates":{"consensusEps":-0.2576,"consensusRevenue":16365.67,"epsLow":-0.4,"epsHigh":-0.0258,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Merck & Co., Inc. (MRK) is a leading global healthcare company that develops innovative medicines and vaccines. With a market cap of $334 billion, it plays a crucial role in the pharmaceuticals sector, focusing on areas like oncology, vaccines, and infectious diseases.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and financial health, especially given the current consensus estimate of a loss.","consensus":"-$0.26"},{"name":"Revenue","why":"Revenue figures will provide insight into the company's sales performance and market demand for its products.","consensus":"$16.4B"}],"lastQuarterRecap":{"summary":"In Q1 2026, Merck reported an EPS of -$1.28, which was better than analysts' expectations of -$1.51. The stock reacted negatively, dropping 1.60% the following day.","promises":["Focus on improving product pipeline and addressing market challenges.","Commitment to enhancing operational efficiency.","Plans to invest in research and development for new therapies."]},"wallStreetExpectations":{"summary":"Analysts are cautiously optimistic about Merck's upcoming earnings, expecting a slight revenue increase but a continued loss in EPS. The market is closely watching how the company navigates its product pipeline and operational challenges.","bullCase":"If Merck can exceed revenue expectations and show signs of profitability improvement, it could lead to a positive stock reaction and renewed investor confidence.","bearCase":"Conversely, if the company fails to meet revenue targets or reports a larger-than-expected loss, it could lead to a significant decline in stock price."},"optionsSignal":{"impliedMove":"11.6%","context":"The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+15.46%","reaction":"-1.60%"},{"quarter":"Q4-2025","epsSurprise":"+0.59%","reaction":"+2.18%"},{"quarter":"Q3-2025","epsSurprise":"+9.32%","reaction":"-0.35%"},{"quarter":"Q2-2025","epsSurprise":"+4.67%","reaction":"-1.70%"},{"quarter":"Q1-2025","epsSurprise":"+3.06%","reaction":"+1.40%"}],"pivotalQuestions":[{"question":"Will Merck's revenue exceed the consensus estimate of $16.4 billion?","whyItMatters":"A revenue beat would indicate strong demand for its products and could boost investor confidence."},{"question":"What is the outlook for EPS, particularly in light of the consensus estimate of -$0.26?","whyItMatters":"Guidance on EPS will be critical as it reflects the company's ability to manage costs and improve profitability."}],"thesisBreakLevels":{"bullTrigger":"Revenue exceeding $16.4 billion with a path towards profitability would confirm the bull case.","bearTrigger":"An EPS loss greater than -$0.26 would solidify the bear case.","context":"The market is debating whether Merck can turn around its financial performance amid ongoing challenges in the pharmaceutical sector."},"scenarioPlaybook":{"beatAndRaise":"If Merck beats expectations, history suggests the stock could rise by an average of 2.67% the following day, confirming a positive outlook.","inLineCautious":"If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.","miss":"A miss on EPS could lead to a decline, with historical data indicating an average drop of 1.60% following disappointing results."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating Merck's potential for revenue growth due to its strong pipeline of new therapies that could drive sales.","supportingPoints":["Recent product launches have shown promising early sales, suggesting stronger demand than anticipated.","The company's focus on operational efficiency may lead to better-than-expected cost management.","Options pricing indicates a higher expected move than historical averages, suggesting traders anticipate significant news."],"riskToConsensus":"If Merck's revenue comes in significantly above $16.4 billion, it could challenge the current bearish sentiment."},"whatToListenFor":["Any updates on the performance of new product launches.","Management's commentary on cost management strategies.","Insights into the pipeline for upcoming therapies.","Guidance on future revenue expectations.","Responses to market competition and pricing pressures."],"metaDescription":"Merck (MRK) reports Q2 2026 earnings on August 4. Analysts expect a loss of $0.26 EPS on $16.4B revenue. Here's what to watch."}}